GlassScriptPhysician profile
Loy Pham
NPI 1982648374
$3,172.25
in general payments reported to CMS, 2019-2025
25 companies · $453 in 2025
The $453 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $396 · 2021: $542 · 2022: $406 · 2023: $348 · 2024: $460 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117 · Travel and Lodging: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.65 |
| Travel and Lodging | $143.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.68 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $379.92 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $316.18 | 2020-2025 | Slynd, Nuvessa |
| Avion Pharmaceuticals | $254.16 | 2019-2022 | |
| Pfizer INC. | $210.77 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $208.26 | 2021-2025 | |
| Applied Medical Resources Corporation | $164.61 | 2023-2024 | Gelpoint V-Path |
| Davol INC. | $148.40 | 2020 | |
| Organon LLC | $131.26 | 2023-2025 | Nexplanon |
| Allergan, INC. | $112.70 | 2019-2020 | |
| Lupin INC. | $99.24 | 2019-2020 | |
| Therapeuticsmd, INC. | $78.91 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $77.40 | 2019-2022 | |
| Biotissue Holdings INC. | $73.60 | 2025 | |
| Coopersurgical, INC. | $71.26 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $52.67 | 2020-2024 | Thinprep 2000 Processor, Aptima |
| Myovant Sciences INC. | $44.40 | 2021-2022 | |
| Millicent US INC | $44.28 | 2025 | Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $40.91 | 2022 | |
| Astellas Pharma US INC | $23.57 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.35 | 2019 | |
| Sage Therapeutics, LLC | $19.45 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $17.78 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $17.19 | 2021 | |
| Merck Sharp & Dohme LLC | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loy Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.